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Regulatory T cells control immune responses
to self- and foreign-antigens and play a major role
in maintaining the balance between immunity
and tolerance. This article reviews recent key de-
velopments in the field of CD4+CD25+Foxp3+
regulatory T (TREG) cells. It presents their charac-
teristics and describes their range of activity and
mechanisms of action. Some models of diseases
triggered by the imbalance between TREG cells
and effector pathogenic T cells are described and
their potential therapeutic applications in humans
are outlined.
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Summary
The existence of cell-subsets specialised in
suppressing immune responses was postulated in
the early seventies by Gershon and colleagues [1].
Nevertheless, convincing evidence came only in
the mid eighties from data obtained by Sakaguchi
et al. [2] and by Don Mason and colleagues [3, 4]
using experimental autoimmune disease mouse or
rat models. Progress was hampered until the mid-
nineties by the lack of reliable phenotypical mark-
ers. The breakthrough in the modern era of regu-
latory T cells is almost certainly due to the work
of Sakaguchi and colleagues, who in 1995 de-
scribed a subpopulation of CD4+ T cells with high
cell surface expression of the interleukin-2 recep-
tor (IL-2R) a-chain, also called CD25, which was
essential for the prevention of autoimmunity [5]. 
This review focuses on naturally occurring
CD4+CD25+ Foxp3+ T (TREG) cells. It stresses re-
cent key progress in defining their characteristics
and focuses on the transcription factor Foxp3, IL-
2 and the components of the high-affinity IL-2
receptor, as these molecules are essential for the
development, function and survival of TREG cells.
It also describes the TREG cells’ mechanisms of ac-
tion and their potential therapeutic applications
either in enhancing their regulatory activity in in-
flammatory diseases such as autoimmunity, allo-
graft rejection, graft versus host disease (GVHD)
and allergic diseases, or in blocking their suppres-
sive activity in tumour immunity or vaccine de-
velopment.
A definition according to function
Immunoregulation is an active process in
which one population of cells controls the activity
of another cell population. So far, various popula-
tions of T cells with regulatory properties have
been characterised in vitro and in vivo and have
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been implicated in the control of autoimmune
diseases, allotransplantation tolerance and anti-
tumour immune responses. Naturally occurring
regulatory T cells have been identified in non-
manipulated rodents and humans, and comprise
cells of the adaptive immune system (CD4+CD25+
Foxp3+ T cells) and of the innate immune system
(natural killer [NK] T cells) [6-8]. Apart from
these spontaneously arising regulatory T cells, it
has been reported that an uncommitted T cell can
be skewed towards a regulatory function by in
vitro or in vivo manipulation. Repetitive in vitro
stimulation with immature dendritic cells (DC) or
in the presence of suppressive cytokines such as
IL-10 or TGF-b can induce regulatory T cells. In
vivo, these cells have been identified in the course
of tolerance induction protocols. Regulatory T
cells of the CD4+ subset, such as Tr1 and Th3
cells [9–11], CD8+ (CD8+CD28- T cells) [12],
double negative CD3+CD4-CD8- T cells [13], 
and gd T cell [14] subsets have been functionally
characterised in in vitro and in vivo settings. We
will not discuss these cells further and will focus
on the naturally occurring CD4+CD25+ Foxp3+ T
cells (TREG).
TREG cells are defined operationally by their
functional ability to regulate/suppress immune
responses. Per se, TREG cells are hyporesponsive
to T cell receptor (TCR) stimulation in vitro, but
exogenous IL-2, strong co-stimulation with in-
creasing concentrations of anti-CD28 mono-
clonal antibody (mAb) or stimulation bypassing
the TCR (such as mitogens) can overcome their
anergic state [7]. On polyclonal or antigen-spe-
cific TCR stimulation, TREG cells potently sup-
press the proliferation and cytokine production of
effector CD4+ and CD8+ T cells by inhibiting IL-2
gene transcription [15-18]; they also inhibit the
proliferation and antibody production of B cells
[19]. The induction of the suppressive function of
TREG is antigen-specific and TREG cells appear to
have a higher avidity for specific antigens as com-
pared to their CD4+CD25- counterparts, as their
suppressive activity is elicited at a 10–100-fold
lower concentration of a specific peptide [18].
Several studies have implied that the regulation
mediated by TREG cells was dependent on a con-
tinuous supply of allo-antigens [20] or tissue-spe-
cific target auto-antigens [21, 22], as removal of
the source of tissue antigens may lead to rapid
contraction of the pool of tissue-specific TREG
cells.
In contrast to their in vitro resistance to pro-
liferation upon TCR stimulation, TREG cells show
active proliferation in vivo following antigenic
stimulation [23, 24]. Naturally arising TREG cells
play a key role in the maintenance of peripheral
dominant tolerance to self- and alloantigens in
vivo (reviewed in [7, 25]). Depletion of
CD4+CD25+ T cells induces effective tumour im-
munity [26–29], enhances immune responses to
invading microbes, triggers allergic responses to
innocuous environmental substances and breaks
foeto-maternal tolerance during pregnancy [30].
On the other hand, TREG cells have been found to
suppress a number of T cell-mediated immune
pathologies, including allergic responses and auto-
immune diseases such as type 1 diabetes (T1D)
[31], experimental autoimmune encephalomyelitis
(EAE) [32-34], gastritis, colitis [35], glomerulo -
nephritis, and polyarthritis [5, 36] as well as allo-
graft rejection [37–40] and GVHD [41–43]. 
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Phenotypic characterisation
Naturally occurring CD4+CD25+ T cells de-
velop in the thymus [44] and constitute some 5–
10% of peripheral CD4+ T cells in non-manipu-
lated normal mice and humans [45-47], but in hu-
mans only the CD4+CD25high cells which consti-
tute 2-3 % of the CD4+ T cells are really regula-
tory [48]. To date the best surface marker correlat-
ing with suppressive activity is CD25 (Figure 1).
However, this marker is not specific as its up-reg-
ulation following cell activation does not confer
regulatory properties, and it has been demon-
strated that cells with regulatory properties can
also be found in the CD4+CD25- T cell pool [49,
50]. The naturally occurring CD4+CD25+ T cell
population also expresses the cytotoxic T lympho-
cyte-associated antigen-4 (CTLA-4) [35, 51] and
the glucocorticoid-induced tumour necrosis fac-
tor (GITR) [52, 53], but, like CD25, these mole-
cules are also up-regulated following activation of
naïve CD4+CD25- T cells. When compared to the
CD4+CD25- population, the TREG population ex-
presses low levels of CD45RB and contains in-
creased frequencies of CD62Lhigh T, indicating an
activated/primed or memory state. 
The aEb7-integrin (CD103), an integrin which
recognises epithelial cadherin responsible for tis-
sue-specific retention of lymphocytes, was shown
to identify a subpopulation of TREG cells [54] and
to be important in the homing and retention of
TREG cells in inflamed tissues [55]. CD103 is ex-
pressed in more than 90% of intestinal and ex-
traintestinal (bronchi, inflammatory skin/breast/
salivary glands, tumour epithelium) intraepithelial
T lymphocytes, while it is only expressed by 0.5–
5% of lymphocytes in peripheral blood and lym-
phoid organs. TREG cells also express specific
chemokine receptors such as CCR4, CCR5 and
CCR8. Mature DC producing CCL17 and
CCL22 were found to preferentially attract TREG
cells to sites of antigen presentation in secondary
lymphoid organs and peripheral inflamed areas
[56]. TREG cells have also been shown to be at-
tracted by CCL4, a chemokine expressed by acti-
vated B cells, DC and macrophages [19], and their
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homing to allografts was dependent on the CCR4
chemokine receptor pathway [57]. 
More recently, LAG-3 (CD223) a cell surface
CD4-related molecule that binds the major histo-
compatibility complex (MHC) class II was shown
to be selectively expressed on TREG cells up on ac-
tivation and to be involved in their suppressive
function [58]. Lechler’s group has also reported
that a member of the b-galactoside-binding pro-
teins, galectin-1, was constitutively overexpressed
in TREG cells and was an important effector of reg-
ulation mediated by these cells [59]. Also, two
groups have recently described a critical role for
the Wiskott-Aldrich Syndrome Protein (WASP)
in the activation and suppressor function of TREG
cells which implicates TREG cell dysfunction in the
autoimmunity associated with the Wiskott-
Aldrich syndrome [60, 61]. 
Key roles of Foxp3 and of the 
IL-2/IL-2 receptor components
In addition to CD25 expressed on the cell
surface, the transcription factor Foxp3 was shown
to be a highly specific intracellular marker for
TREG cells [62-64]. Foxp3, the cytokine IL-2, and
CD25 as a component of the IL-2 receptor, are
essential for the development, function and sur-
vival of TREG cells because mutation or polymor-
phisms in the genes encoding these molecules are
causative of, or predispose to, autoimmune dis-
eases in both rodents and humans. The Foxp3
gene was identified as the defective gene in the
scurfy mouse strain, whose phenotype is an X-
linked recessive mutant with lethality in males
within a month after birth due to excessive activa-
tion of CD4+ T cells and overproduction of pro-
inflammatory cytokines [65]. Mutations of the
human ortholog Foxp3 gene were subsequently
found to be the cause of the immune dysregula-
tion, polyendocrinopathy, and enteropathy, X-
linked recessive (IPEX) and the X-linked autoim-
munity-allergic dysregulation (XLAAD) syn-
dromes. Patients carrying these mutations develop
organ-specific autoimmune diseases such as T1D,
thyroiditis, inflammatory bowel disease (IBD), al-
lergic dermatitis, food allergy, haematological dis-
orders, and serious infections [66–68]. The spe-
cific role of Foxp3 in the function of TREG cells
was highlighted by the fact that retroviral trans-
duction of Foxp3 into CD4+CD25- T cells can
convert them to functional TREG cells able to sup-
press proliferation of other T cells in vitro and in-
hibit the development of autoimmune diseases,
such as colitis or T1D, mediated by pathogenic
effector T cells in in vivo experimental models [7,
63].
IL-2 has been shown to be essential for the
generation of TREG cells in the thymus and their
survival, expansion and suppressive function in
the periphery [69]. IL-2-, and IL-2R-deficient
mice develop T-cell lympho-proliferation and
lethal autoimmunity, very probably due to lack of
activation-induced cell death (AICD) and lack of
TREG cells [70, 71]. Furthermore, in vivo IL-2 neu-
tralisation by use of an IL-2 blocking antibody
also induces autoimmune diseases in mice [72].
The detailed molecular mechanisms of the effects
of IL-2 in the homeostasis and suppressive func-
tion of TREG cells have still to be clarified. 
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Figure 1
Phenotypic markers
characteristic of natu-
rally occurring TREG
cells.
Mechanisms of regulation 
Contact-dependent versus cytokine-mediated
effect 
TREG cells’ precise mechanisms of action are
still unclear, with divergent conclusions regarding
the importance of cell-cell contact versus cyto -
kines in their suppressive function (Figure 2). The
discrepant results might be explained by differ-
ences in the experimental systems (in vitro versus
in vivo), the various disease models studied, the
pathogenic effector mechanisms and target organs
involved, and the contribution of the genetic
background of the mouse strains used.
Role of cell surface molecules 
In vitro, TREG cells have been shown to inhibit
the activation of effector CD4+CD25- T cells by a
mechanism which depends on cell-cell contact
rather than on soluble mediators [16]. CTLA-4
[35, 51], membrane-bound transforming growth
factor-b (TGF-b) [73], GITR [52, 53], and
galectin-1 [59] appear to be functionally impor-
tant molecules since in various models mono-
clonal antibodies (mAbs) against these molecules
have been shown to overcome the suppression
mediated by TREG cells in vitro and/or in vivo.
Moreover, after activation, human TREG cells were
shown to be able to directly kill activated CD4+
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inflamed tissues
GITR
CTLA-4
LAG-3
Galectin-1
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CCR5
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and CD8+ T cells in a perforin or granzyme-de-
pendent way [74]. 
Direct T-T interactions via surface molecules
may mediate suppression in vitro, since activated
TREG cells have been shown to suppress the prolif-
eration of effector T cells in response to TCR
stimulation in the complete absence of antigen-
presenting cells (APC) [7]. TREG cells may also
down-modulate the function of APC and render
them unable to activate effector T cells. It was
shown that co-culture with activated TREG cells
leads to reduced amounts of costimulatory mole-
cules on DC and B cells [75], inhibiting their im-
munogenic properties. “Tolerogenic” DCs may in
turn induce other regulatory cells, thus contribut-
ing to the maintenance of tolerance. In vivo, how-
ever, it is likely that more complex interactions
between TREG cells, effector T cells and APC/DC
determine the resulting immune response (“mé-
nage à trois”). Another way in which TREG cells
could mediate their immune suppressive proper-
ties is to induce differentiation of naive T cells
into cells with a regulatory function rather than
into pathogenic effector T cells. This phenome-
non has been termed “infectious tolerance”, and
obvious candidate molecules mediating this effect
may be regulatory cytokines such as IL-10 or
TGF-b [76–78]. 
CTLA-4
A large proportion of TREG cells express
CTLA-4 in both mouse and human. CTLA-4 is
known to be a negative regulator of T-cell activa-
tion but also to play a key role in immunological
self-tolerance. Non-activating anti-CTLA-4 mAbs
have been shown to block the suppressor activity
of TREG cells in vitro and in vivo [35, 51], and mice
deficient in CTLA-4 develop a fatal lymphopro-
liferative disease and multiorgan inflammation
[79]. The role of CTLA-4 expression in the
homeostasis and function of TREG cells remains
however controversial [80]. 
Role of soluble cytokines (IL-10, TGF-b)
IL-10
In vivo models of colitis [81-83] and infection
[84] show that IL-10 is often crucial for the main-
tenance of immune homeostasis and regulation
mediated by TREG cells. In some transplantation
models anti-IL-10 or anti-IL-10R mAbs abro-
gated the induction of peripheral tolerance by
otherwise previously proven robust tolerogenic
protocols [39]. IL-10 is produced by a large num-
ber of immune cells such as T cells, monocytes,
macrophages and epithelial cells, and has
pleiotropic effects on B, T and NK cells, DC and
mast cells. Signalling through the IL-10/IL-10R
results in potent inhibition of cell proliferation, of
pro-inflammatory cytokine production and of the
maturation and antigen presentation of DC [78].
IL-10 also plays a pivotal role in TREG cell func-
tion, CD4+CD25+ T cells from IL-10-/- mice hav-
ing been shown to be significantly less potent
than their wild type counterparts. Using a T cell-
mediated model of murine colitis, Powrie’s group
has shown that intestinal inflammation mediated
by the transfer of naïve CD4+CD25- T cells can
be cured by the transfer of TREG cells. In this
model, during the cure of colitis, IL-10-secreting
Foxp3+ T cells selectively enriched within the
colonic lamina propria. The administration of an
anti-IL-10R mAb to mice treated with TREG cells
completely abolished the cure. These findings
were further confirmed by analysis of human
colonic samples, where an accumulation of
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Foxp3+CD4+CD25+ T cells was found in the lam-
ina propria of patients with IBD, diverticulitis,
pseudomembranous and CMV colitis [85, 86].
TGF-b
TGF-b is the prototype of a family of
polypeptides involved in growth control, extracel-
lular matrix production and development. Three
isoforms of TGF-b exist in mammals (TGF-b1, -
b2, and -b3) and TGF-b1 has been identified as
an immunoregulatory molecule with both im-
munogenic and immunosuppressive properties
depending on the cellular environment [77]. Most
models of immune regulation showing a role of
IL-10 also implicate TGF-b, the production and
action of these two cytokines being interrelated
and likely to involve positive feedback loops in
which IL-10 enhances expression of TGF-b and
vice versa. IL-10 may act locally at the site of in-
flammation, while TGF-b seems to have a more
systemic effect on the immune response. The
suppressive activity of TGF-b is best highlighted
by the fact that TGF-b-deficient mice develop a
lethal lymphoproliferative disease [87]. The re-
sults concerning the requirement for TGF-b ex-
pression by TREG in vitro and in vivo are contro-
versial [73, 88, 89], and it appears that regulation
is dictated primarily by the responsiveness of the
effector T cell to TGF-b [90, 91].
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Models of diseases triggered by imbalance between TREG
and effector T cells 
Autoimmune and allergic diseases
There is now a mass of evidence that TREG ac-
tively suppress the activation and expansion of
self-reactive T cells in vivo and thereby the devel-
opment of autoimmune diseases. Neonatal
thymectomy or depletion of TREG cells from nor-
mal animals result in spontaneous development of
various organ-specific autoimmune diseases (such
as gastritis, IBD, T1D, EAE, myocarditis, depend-
ing on the genetic background of the strains of
mice used) and increase alloresponses to skin allo-
grafts [5, 7] (Figure 3). In these cases, autoimmu-
nity is prevented by reconstitution of the mice
with wild type TREG cells. In the regulation of al-
lergy TREG cells have been shown to be effective in
suppressing the production of antigen-specific
IgE in TCR transgenic murine models [92]. 
In humans, a study by Danke et al. illustrates
the fact that T cells reactive to target self-anti-
gens, such as glutamic acid decarboxylase, which
is involved in T1D, could be easily expanded in
vitro from peripheral blood of normal individuals
only after depleting the CD25+ subset [93]. These
results indicate that self-reactive T cells are pres-
ent in most individuals but their pathogenic po-
tential is kept in check by coexisting TREG cells.
IPEX as a prototype of disease induced by an in-
trinsic defect of TREG cells is thus far the clearest
example showing that an abnormality in the pool
of naturally arising TREG cells is a primary cause of
autoimmune diseases in humans, and that TREG
cells are crucial in the maintenance of dominant
self-tolerance. Alterations in the numbers or func-
tional activity of TREG cells, in peripheral blood or
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target organs, have also been associated with sev-
eral human chronic inflammatory and autoim-
mune diseases such as multiple sclerosis [94],
rheumatoid arthritis [95-97], T1D [98], IBD [99],
systemic lupus erythematosus [100], polyglandular
syndrome type II [101], myasthenia gravis [102],
allergic asthma [103], cow’s milk allergy [104],
nickel allergy [105] and atopic dermatitis [106]. 
Infectious diseases
TREG cells probably participate in the immune
response to all infectious agents, since apart from
regulating adaptive immune responses they have
been shown to be also capable of directly sup-
pressing innate immune responses in a model of
murine pathogen-mediated colitis [84]. How
TREG cell activity is regulated to allow effective
immune responses towards pathogens without
pathological anti-self reactivity has baffled immu-
nologists [107]. 
Activation of DCs through Toll like Receptor
(TLR) signalling can overcome dominant TREG
cell suppression in vitro and enhance effector T
cell responses [108]. TREG cells appear however to
restrain too vigorous immune reactivity, which in
many chronic infections will benefit the host by
limiting tissue damage. Current evidence suggests
that in the course of an infection TLR signalling
would directly regulate the suppressive function
of TREG cells by augmenting TREG cell prolifera-
tion with a temporal loss of their suppressive ac-
tivity. The TREG cells would recover their suppres-
sive activity when the infection has subsided, in
time to limit potential autoimmunity that could
result from overactivated effector mechanisms. It
therefore appears that the balance between TREG
cells and effector T cells depends on the activa-
tion status of the innate immune system and par-
ticularly the DC.
In many chronic infections TREG cells appear
to restrain immune reactivity in order to limit
host tissue damage, but this may handicap the ef-
ficacy of protective immunity and clearance of
pathogens [107]. Studies on persistent chronic in-
fections, such as herpes simplex virus (HSV), hep-
atitis C virus (HCV) and HIV, have shown that
the presence of TREG cells at the time of infection
may affect the magnitude of protective immunity
and the outcome of infection [109–113]. When
TREG cells were depleted, animals developed
memory responses and could subsequently mount
better recall responses. TREG cells were increased
in number and activity in chronic HCV patients
compared to controls who resolved their infec-
tions. Such TREG cells isolated from peripheral
blood, and in one instance from the liver itself,
modulated peptide-specific proliferative re-
sponses and maturation of HCV-specific CD8+ T
cells. Similarly, reduction of tissue-damaging
 immunopathology by TREG cell function has been
observed in some parasitic infections such as
Pneumocystis carinii, Leishmania major and
Schistosoma masoni [114, 115]. 
Transplantation 
In the transplant setting, circulating alloreac-
tive T cells are crucial in the initiation and the co-
ordination of the rejection response and, to pro-
mote tolerance, it is important to deplete or min-
imise the alloreactive effector T cell pool while
enhancing regulatory mechanisms. Various strate-
gies, targeting T cell activation, expansion and/or
effector function, have been described as a means
of achieving robust peripheral transplantation
tolerance in experimental protocols [116]. More
recent studies have shown that in many of these
protocols immunoregulatory mechanisms de-
pendent on TREG cells were critical in the induc-
tion and maintenance of peripheral tolerance.
Thus, after a short course of immunomodulatory
drugs, such as non-depleting anti-T cell mAbs or
costimulatory blockade, donor alloantigen-spe-
cific TREG cells are generated which are capable,
on adoptive transfer, of suppressing rejection of
donor allografts mediated by naïve recipient
CD4+ or CD8+ T cells [37–40]. We have also re-
ported that in vivo allo-responses can be har-
nessed by donor alloantigen-specific TREG cells
selected and expanded in vitro [117].
In murine models of allogeneic bone marrow
transplantation (BMT), it has similarly been
shown that freshly isolated or ex-vivo expanded
donor-derived TREG cells can delay or even pre-
vent GVHD, and that the selective depletion of
TREG cells in the transplant results in increased
severity of acute GVHD [41–43]. Patients who
developed acute or chronic GVHD after allo-
geneic BMT had a decreased number of periph-
eral and tissue infiltrating TREG cells [118, 119].
Intestinal mucosal specimens without histological
signs of GVHD showed increased ratios of
FOXP3+/CD8+ T cells compared to samples with
histological signs of acute and chronic GVHD,
providing further evidence that GVHD lesions
are associated with lack of regulation by TREG
cells. 
Tumour immunity 
Depletion of TREG cells using CD25-specific
mAbs has been shown to promote rejection of
several transplantable murine tumour cell lines,
including melanoma, fibrosarcoma, leukaemia
and colorectal carcinoma. These studies imply
that TREG cells normally inhibit the generation of
effective T cell-dependent anti-tumour immune
responses [27–29]. These finding have been con-
firmed in the clinical setting, where the preva-
lence of TREG cells was found to be increased in
the peripheral blood and tumour microenviron-
ment of cancer patients [26, 120–123].
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Approaches to prevention or treatment of 
T cell-mediated diseases, such as autoimmunity
and transplant rejection, have focused historically
on potent immunosuppressive drugs non-specifi-
cally targeting T cell responses. However, the im-
proved survival rates of allografts and the better
outcome of autoimmune diseases have come at a
cost, with increased frequencies of drug-related
adverse effects. A better understanding of the role
of naturally occurring TREG cells in the mainte-
nance of immune homeostasis has prompted re-
searchers to investigate their therapeutic poten-
tial. TREG cells could be used as an immunothera-
peutic tool, either by enhancing their activity in
inflammatory diseases such as autoimmunity, allo-
graft rejection or GVHD, or by blocking their
suppressive activity in tumour immunity or vac-
cine development. 
If TREG cells are to be used in immunotherapy
aiming at the prevention or treatment of autoim-
mune diseases or allograft rejection, antigen-spe-
cific cells are needed which can specifically con-
trol immune responses to the relevant auto- or
allo-antigens, while allowing protective immune
responses to pathogens. Furthermore, because of
the low precursor frequency of alloantigen cross-
reactive TREG cells expected in a normal individ-
ual without prior antigen exposure, this specific
population needs to be expanded in vivo or gener-
ated in large numbers in vitro for adoptive trans-
fer. New experimental evidence has shown, in var-
ious experimental settings, that antigen-specific
TREG cells can be generated and expanded in suffi-
cient quantities in vitro without loss of their char-
acteristic phenotype and regulatory properties
[117, 124–126]. Importantly, we have shown that
in vitro manipulations did not modify their in vivo
homeostasis, migration patterns or suppressive
functions, as demonstrated by adoptive transfer
experiments [117]. Alternatively, immunomodula-
tory drugs, such as rapamycin, could be used to
selectively expand TREG cells in vivo while control-
ling the effector T cell pool [127]. 
The other side of the coin is that there is now
substantial evidence to show that the presence of
TREG cells is deleterious in cancer patients and
contributes to the unsuccessful immune responses
in some chronic persistent infections. Therefore,
depletion of TREG cells in combination with other
anti-tumour therapies could optimise eradication
of malignancies. Depletion of TREG cells can also
be used to boost immune responses in vaccine de-
velopment or to enhance protective immune re-
sponses against invading microbes. This may,
however, prevent the induction of long-term in-
fectious immunity or favour the development of
autoimmune diseases.
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Conclusion
These novel therapeutic approaches are not
without risks. The key to success will be to estab-
lish the correct balance between TREG cells and ef-
fector cells. These exciting new therapeutic con-
cepts will undoubtedly act as a spur to the transla-
tional research community over the next few
years. Indeed, steady progress in our understand-
ing of TREG cell function in vivo and their dynam-
ics with pathogenic T cells provides the rationale
for a novel form of individualised “tailored” medi-
cine using TREG cell-based therapies in the pre-
vention and treatment of autoimmune diseases
and in transplantation. 
Correspondence:
Dela Golshayan, MD
Division of Nephrology and 
Transplantation Centre, 
Centre Hospitalier Universitaire Vaudois
(CHUV)
CH-1011 Lausanne
Switzerland
E-Mail: dela.golshayan@chuv.ch
References
1 Gershon RK. A disquisition on suppressor T cells. Transplant
Rev. 1975;26:170–85.
2 Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T. Organ-spe-
cific autoimmune diseases induced in mice by elimination of T
cell subset. I. Evidence for the active participation of T cells in
natural self-tolerance; deficit of a T cell subset as a possible
cause of autoimmune disease. J Exp Med. 1985;161:72–87.
3 Fowell D, Mason D. Evidence that the T cell repertoire of nor-
mal rats contains cells with the potential to cause diabetes.
Characterization of the CD4+ T cell subset that inhibits this
autoimmune potential. J Exp Med. 1993;177:627–36.
4 Powrie F, Mason D. OX-22high CD4+ T cells induce wasting
disease with multiple organ pathology: prevention by the OX-
22low subset. J Exp Med. 1990;172:1701–8.
5 Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immu-
nologic self-tolerance maintained by activated T cells expres-
sing IL-2 receptor alpha-chains (CD25). Breakdown of a single
mechanism of self-tolerance causes various autoimmune disea-
ses. J Immunol. 1995;155:1151–64.
6 Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-spe-
cific NK1 T cells: development, specificity, and function. Annu
Rev Immunol. 1997;15:535–62.
Therapeutic potential of TREG cells 
625-634 Mot 11916-07.qxp  8.11.2007  9:23 Uhr  Seite 631
7 Sakaguchi S. Naturally arising CD4+ regulatory T cells for im-
munologic self-tolerance and negative control of immune re-
sponses. Annu Rev Immunol. 2004;22:531–62.
8 Shevach EM: CD4+ CD25+ suppressor T cells: more questi-
ons than answers. Nat Rev Immunol. 2002;2:389–400.
9 Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, De
Vries JE, et al. A CD4+ T-cell subset inhibits antigen-specific
T-cell responses and prevents colitis. Nature. 1997;389:737–
42.
10 Roncarolo MG, Gregori S, Levings M. Type 1 T regulatory
cells and their relationship with CD4+CD25+ T regulatory
cells. Novartis Found Symp 2003;252:115–27; discussion 127-
131, 203-110.
11 Weiner HL. Induction and mechanism of action of transfor-
ming growth factor-beta-secreting Th3 regulatory cells. Im-
munol Rev. 2001;182:207–14.
12 Liu Z, Tugulea S, Cortesini R, Suciu-Foca N. Specific suppres-
sion of T helper alloreactivity by allo-MHC class I-restricted
CD8+CD28- T cells. Int Immunol. 1998;10:775–83.
13 Zhang ZX, Yang L, Young KJ, DuTemple B, Zhang L. Identifi-
cation of a previously unknown antigen-specific regulatory T
cell and its mechanism of suppression. Nat Med. 2000;6:782–9.
14 Hayday A, Tigelaar R. Immunoregulation in the tissues by
gammadelta T cells. Nat Rev Immunol. 2003;3:233–42.
15 Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Ot-
suka F, et al. Thymus and autoimmunity: production of
CD25+CD4+ naturally anergic and suppressive T cells as a key
function of the thymus in maintaining immunologic self-tole-
rance. J Immunol. 1999;162:5317–26.
16 Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory
T cells suppress polyclonal T cell activation in vitro by inhibi-
ting interleukin 2 production. J Exp Med. 1998;188:287–96.
17 Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T
cell activation by CD4+CD25+ immunoregulatory cells. J Im-
munol. 2001;167:1137–40.
18 Thornton AM, Shevach EM. Suppressor effector function of
CD4+CD25+ immunoregulatory T cells is antigen nonspeci-
fic. J Immunol. 2000;164:183–90.
19 Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG. B
cells and professional APCs recruit regulatory T cells via
CCL4. Nat Immunol. 2001;2:1126–32.
20 Scully R, Qin S, Cobbold S, Waldmann H. Mechanisms in
CD4 antibody-mediated transplantation tolerance: kinetics of
induction, antigen dependency and role of regulatory T cells.
Eur J Immunol. 1994;24:2383–92.
21 Green EA, Choi Y, Flavell RA. Pancreatic lymph node-derived
CD4(+)CD25(+) Treg cells: highly potent regulators of diabe-
tes that require TRANCE-RANK signals. Immunity. 2002;16:
183–91.
22 Seddon B, Mason D. Peripheral autoantigen induces regula-
tory T cells that prevent autoimmunity. J Exp Med. 1999;189:
877–82.
23 Fisson S, Darrasse-Jeze G, Litvinova E, Septier F, Klatzmann
D, Liblau R, et al. Continuous activation of autoreactive CD4+
CD25+ regulatory T cells in the steady state. J Exp Med.
2003;198:737–46.
24 Walker LS, Chodos A, Eggena M, Dooms H, Abbas AK. Anti-
gen-dependent proliferation of CD4+ CD25+ regulatory T
cells in vivo. J Exp Med. 2003;198:249–58.
25 Maloy KJ, Powrie F. Regulatory T cells in the control of im-
mune pathology. Nat Immunol. 2001;2:816–22.
26 Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P,
et al. Specific recruitment of regulatory T cells in ovarian car-
cinoma fosters immune privilege and predicts reduced survival.
Nat Med. 2004;10:942–9.
27 Gallimore A, Sakaguchi S. Regulation of tumour immunity by
CD25+ T cells. Immunology. 2002;107:5–9.
28 Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Na-
kayama E. Tumor rejection by in vivo administration of anti-
CD25 (interleukin-2 receptor alpha) monoclonal antibody.
Cancer Res. 1999;59:3128–33.
29 Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immu-
nity by removing CD25+CD4+ T cells: a common basis bet-
ween tumor immunity and autoimmunity. J Immunol. 1999;
163:5211–8.
30 Zenclussen AC. CD4(+)CD25+ T regulatory cells in murine
pregnancy. J Reprod Immunol. 2005;65:101–10.
31 Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B,
Sharpe A, et al. B7/CD28 costimulation is essential for the
homeostasis of the CD4+CD25+ immunoregulatory T cells
that control autoimmune diabetes. Immunity. 2000;12:431–40.
32 Furtado GC, Olivares-Villagomez D, Curotto de Lafaille MA,
Wensky AK, Latkowski JA, Lafaille JJ. Regulatory T cells in
spontaneous autoimmune encephalomyelitis. Immunol Rev.
2001;182:122–34.
33 Hori S, Haury M, Lafaille JJ, Demengeot J, Coutinho A. Peri-
pheral expansion of thymus-derived regulatory cells in anti-
myelin basic protein T cell receptor transgenic mice. Eur J Im-
munol. 2002;32:3729–35.
34 Kohm AP, Carpentier PA, Anger HA, Miller SD. Cutting edge:
CD4+CD25+ regulatory T cells suppress antigen-specific au-
toreactive immune responses and central nervous system in-
flammation during active experimental autoimmune encepha-
lomyelitis. J Immunol. 2002;169:4712–6.
35 Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-as-
sociated antigen 4 plays an essential role in the function of
CD25(+)CD4(+) regulatory cells that control intestinal inflam-
mation. J Exp Med. 2000;192:295–302.
36 Suri-Payer E, Amar AZ, Thornton AM, Shevach EM.
CD4+CD25+ T cells inhibit both the induction and effector
function of autoreactive T cells and represent a unique lineage
of immunoregulatory cells. J Immunol. 1998;160:1212–8.
37 Cobbold SP, Graca L, Lin CY, Adams E, Waldmann H. Regu-
latory T cells in the induction and maintenance of peripheral
transplantation tolerance. Transpl Int. 2003;16:66–75.
38 Graca L, Cobbold SP, Waldmann H. Identification of regula-
tory T cells in tolerated allografts. J Exp Med. 2002;195:1641–
6.
39 Kingsley CI, Karim M, Bushell AR, Wood KJ. CD25+CD4+
regulatory T cells prevent graft rejection: CTLA-4- and IL-
10-dependent immunoregulation of alloresponses. J Immunol.
2002;168:1080–6.
40 Wood KJ, Sakaguchi S. Regulatory T cells in transplantation
tolerance. Nat Rev Immunol. 2003;3:199–210.
41 Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL.
CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics
for graft-versus-host disease. J Exp Med. 2002;196:401–6.
42 Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG,
Strober S, et al. CD4+CD25+ regulatory T cells preserve graft-
versus-tumor activity while inhibiting graft-versus-host disease
after bone marrow transplantation. Nat Med. 2003;9:1144–50.
43 Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo acti-
vated and expanded CD4(+)CD25(+) immune regulatory cells
inhibits graft-versus-host disease lethality. Blood. 2002;99:
3493–9.
44 Fontenot JD, Dooley JL, Farr AG, Rudensky AY. Developmen-
tal regulation of Foxp3 expression during ontogeny. J Exp
Med. 2005;202(7):901–6.
45 Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk
AH. Identification and functional characterization of human
CD4(+)CD25(+) T cells with regulatory properties isolated
from peripheral blood. J Exp Med. 2001;193:1285–94.
46 Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Ed-
wards AD, et al. Human CD4(+)CD25(+) cells: a naturally oc-
curring population of regulatory T cells. Blood. 2001;98:2736–
44.
47 Stephens LA, Mottet C, Mason D, Powrie F. Human
CD4(+)CD25(+) thymocytes and peripheral T cells have im-
mune suppressive activity in vitro. Eur J Immunol. 2001;31:
1247–54.
48 Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA.
CD4+CD25high regulatory cells in human peripheral blood. J
Immunol. 2001;167:1245–53.
49 Graca L, Thompson S, Lin CY, Adams E, Cobbold SP, Wald-
mann H. Both CD4(+)CD25(+) and CD4(+)CD25(-) regula-
tory cells mediate dominant transplantation tolerance. J Im-
munol. 2002;168:5558–65.
50 Stephens LA, Mason D. CD25 is a marker for CD4+ thymocy-
tes that prevent autoimmune diabetes in rats, but peripheral T
cells with this function are found in both CD25+ and CD25-
subpopulations [In Process Citation]. J Immunol. 2000;165:
3105–10.
51 Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Saka-
guchi N, et al. Immunologic self-tolerance maintained by
CD25(+)CD4(+) regulatory T cells constitutively expressing
cytotoxic T lymphocyte-associated antigen 4. J Exp Med.
2000;192:303–10.
52 McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach
EM, Collins M, et al. CD4(+)CD25(+) immunoregulatory T
cells: gene expression analysis reveals a functional role for the
glucocorticoid-induced TNF receptor. Immunity. 2002;16:
311–23.
632CD4+CD25+Foxp3+ regulatory T cells
625-634 Mot 11916-07.qxp  8.11.2007  9:23 Uhr  Seite 632
633
53 Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Sti-
mulation of CD25(+)CD4(+) regulatory T cells through GITR
breaks immunological self-tolerance. Nat Immunol.
2002;3:135–42.
54 Lehmann J, Huehn J, de la Rosa M, Maszyna F, Kretschmer U,
Krenn V, et al. Expression of the integrin alpha Ebeta 7 identi-
fies unique subsets of CD25+ as well as CD25- regulatory T
cells. Proc Natl Acad Sci U S A. 2002;99:13031–6.
55 Suffia I, Reckling SK, Salay G, Belkaid Y. A role for CD103 in
the retention of CD4+CD25+ Treg and control of Leishmania
major infection. J Immunol. 2005;174:5444–55.
56 Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P,
Sinigaglia F, et al. Unique chemotactic response profile and
specific expression of chemokine receptors CCR4 and CCR8
by CD4(+)CD25(+) regulatory T cells. J Exp Med.
2001;194:847–53.
57 Lee I, Wang L, Wells AD, Dorf ME, Ozkaynak E, Hancock
WW. Recruitment of Foxp3+ T regulatory cells mediating al-
lograft tolerance depends on the CCR4 chemokine receptor. 
J Exp Med. 2005;201:1037–44.
58 Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G,
et al. Role of LAG-3 in regulatory T cells. Immunity.
2004;21:503–13.
59 Garin MI, Chu CC, Golshayan D, Cernuda-Morollon E, Wait
R, Lechler RI. Galectin-1: a key effector of regulation media-
ted by CD4+CD25+ T cells. Blood. 2007;109:2058–65.
60 Maillard MH, Cotta-de-Almeida V, Takeshima F, Nguyen DD,
Michetti P, Nagler C, et al. The Wiskott-Aldrich syndrome
protein is required for the function of CD4+CD25+Foxp3+ re-
gulatory T cells. J Exp Med. 2007;204:381–91.
61 Marangoni F, Trifari S, Scaramuzza S, Panaroni C, Martino S,
Notarangelo LD, et al. WASP regulates suppressor activity of
human and murine CD4+CD25+FOXP3+ natural regulatory
T cells. J Exp Med. 2007;204:369–80.
62 Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the
development and function of CD4+CD25+ regulatory T cells.
Nat Immunol. 2003;4:330–6.
63 Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell
development by the transcription factor Foxp3. Science.
2003;299:1057–61.
64 Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for
Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol.
2003;4:337–42.
65 Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB,
Yasayko SA, et al. Disruption of a new forkhead/winged-helix
protein, scurfin, results in the fatal lymphoproliferative disor-
der of the scurfy mouse. Nat Genet. 2001;27:68–73.
66 Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson
PJ, Whitesell L, et al. The immune dysregulation, polyendocri-
nopathy, enteropathy, X-linked syndrome (IPEX) is caused by
mutations of FOXP3. Nat Genet. 2001;27:20–1.
67 Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos
C, Helms C, et al. JM2, encoding a fork head-related protein, is
mutated in X-linked autoimmunity-allergic disregulation syn-
drome. J Clin Invest. 2000;106:R75–81.
68 Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist
N, et al. X-linked neonatal diabetes mellitus, enteropathy and
endocrinopathy syndrome is the human equivalent of mouse
scurfy. Nat Genet. 2001;27:18–20.
69 Malek TR, Bayer AL. Tolerance, not immunity, crucially de-
pends on IL-2. Nat Rev Immunol. 2004;4:665–74.
70 Sadlack B, Lohler J, Schorle H, Klebb G, Haber H, Sickel E, et
al. Generalized autoimmune disease in interleukin-2-deficient
mice is triggered by an uncontrolled activation and prolifera-
tion of CD4+ T cells. Eur J Immunol. 1995;25:3053–9.
71 Suzuki H, Kundig TM, Furlonger C, Wakeham A, Timms E,
Matsuyama T, et al. Deregulated T cell activation and autoim-
munity in mice lacking interleukin-2 receptor beta. Science.
1995;268:1472–6.
72 Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic
maintenance of natural Foxp3+ CD25+ CD4+ regulatory T
cells by interleukin (IL)-2 and induction of autoimmune
disease by IL-2 neutralization. J Exp Med. 2005;201:723–35.
73 Nakamura K, Kitani A, Strober W. Cell contact-dependent im-
munosuppression by CD4(+)CD25(+) regulatory T cells is me-
diated by cell surface-bound transforming growth factor beta. 
J Exp Med. 2001;194:629–44.
74 Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson
JP, Ley TJ. Human T regulatory cells can use the perforin
pathway to cause autologous target cell death. Immunity.
2004;21:589–601.
75 Cederbom L, Hall H, Ivars F. CD4+CD25+ regulatory T cells
down-regulate co-stimulatory molecules on antigen-presen-
ting cells. Eur J Immunol. 2000;30:1538–43.
76 Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk
AH. Infectious tolerance: human CD25(+) regulatory T cells
convey suppressor activity to conventional CD4(+) T helper
cells. J Exp Med. 2002;196:255–60.
77 Letterio JJ, Roberts AB. Regulation of immune responses by
TGF-beta. Annu Rev Immunol. 1998;16:137–61.
78 Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. In-
terleukin-10 and the interleukin-10 receptor. Annu Rev Immu-
nol. 2001;19:683–765.
79 Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone
JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphopro-
liferation and fatal multiorgan tissue destruction, revealing a
critical negative regulatory role of CTLA-4. Immunity.
1995;3:541–7.
80 Boden E, Tang Q, Bour-Jordan H, Bluestone JA. The role of
CD28 and CTLA4 in the function and homeostasis of
CD4+CD25+ regulatory T cells. Novartis Found Symp.
2003;252:55–63; discussion 63–56, 106–114.
81 Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Barbosa
TC, Cumano A, Bandeira A. CD25+ CD4+ T cells regulate the
expansion of peripheral CD4 T cells through the production of
IL-10. J Immunol 2001;166:3008-3018.
82 Asseman C, Fowler S, Powrie F. Control of experimental in-
flammatory bowel disease by regulatory T cells. Am J Respir
Crit Care Med. 2000;162:S185–9.
83 Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleu-
kin-10-deficient mice develop chronic enterocolitis. Cell.
1993;75:263–74.
84 Maloy KJ, Salaun L, Cahill R, Dougan G, Saunders NJ, Powrie
F. CD4+CD25+ T(R) cells suppress innate immune pathology
through cytokine-dependent mechanisms. J Exp Med.
2003;197:111–9.
85 Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by
CD4+CD25+ regulatory T cells. J Immunol. 2003;170:3939–
43.
86 Uhlig HH, Coombes J, Mottet C, Izcue A, Thompson C, Fan-
ger A, et al. Characterization of Foxp3+CD4+CD25+ and IL-
10-secreting CD4+CD25+ T cells during cure of colitis. J Im-
munol. 2006;177:5852–60.
87 Christ M, McCartney-Francis NL, Kulkarni AB, Ward JM,
Mizel DE, Mackall CL, et al. Immune dysregulation in TGF-
beta 1-deficient mice. J Immunol. 1994;153:1936–46.
88 Piccirillo CA, Letterio JJ, Thornton AM, McHugh RS, Ma-
mura M, Mizuhara H, et al. CD4(+)CD25(+) regulatory T cells
can mediate suppressor function in the absence of transfor-
ming growth factor beta1 production and responsiveness. 
J Exp Med. 2002;196:237–46.
89 Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL. A cri-
tical role for transforming growth factor-beta but not interleu-
kin 4 in the suppression of T helper type 1-mediated colitis by
CD45RB(low) CD4+ T cells. J Exp Med. 1996;183:2669–74.
90 Fahlen L, Read S, Gorelik L, Hurst SD, Coffman RL, Flavell
RA, et al. T cells that cannot respond to TGF-{beta} escape
control by CD4+CD25+ regulatory T cells. J Exp Med.
2005;201:737–46.
91 Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T
cells leads to spontaneous T cell differentiation and autoim-
mune disease. Immunity. 2000;12:171–81.
92 Curotto de Lafaille MA, Muriglan S, Sunshine MJ, Lei Y, Kut-
chukhidze N, Furtado GC, et al. Hyper immunoglobulin E re-
sponse in mice with monoclonal populations of B and T lym-
phocytes. J Exp Med. 2001;194:1349–59.
93 Danke NA, Koelle DM, Yee C, Beheray S, Kwok WW. Autore-
active T cells in healthy individuals. J Immunol.
2004;172:5967–72.
94 Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of
functional suppression by CD4+CD25+ regulatory T cells in
patients with multiple sclerosis. J Exp Med. 2004;199:971–9.
95 Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malm-
strom V. CD25brightCD4+ regulatory T cells are enriched in
inflamed joints of patients with chronic rheumatic disease. Ar-
thritis Res Ther. 2004;6:R335–46.
96 de Kleer IM, Wedderburn LR, Taams LS, Patel A, Varsani H,
Klein M, et al. CD4+CD25bright regulatory T cells actively
regulate inflammation in the joints of patients with the remit-
ting form of juvenile idiopathic arthritis. J Immunol.
2004;172:6435–43.
S W I S S  M E D  W K LY 2 0 0 7 ; 13 7 : 6 2 5 – 6 3 4  ·  w w w. s m w. ch
625-634 Mot 11916-07.qxp  8.11.2007  9:23 Uhr  Seite 633
97 Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G,
Isenberg DA, Mauri C. Compromised function of regulatory
T cells in rheumatoid arthritis and reversal by anti-
TNFalpha therapy. J Exp Med. 2004;200:277–85.
98 Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, et
al. Multiple immuno-regulatory defects in type-1 diabetes. 
J Clin Invest. 2002;109:131–40.
99 Makita S, Kanai T, Oshima S, Uraushihara K, Totsuka T, Sa-
wada T, et al. CD4+CD25bright T cells in human intestinal
lamina propria as regulatory cells. J Immunol. 2004;173:
3119–30.
100 Crispin JC, Martinez A, Alcocer-Varela J. Quantification of
regulatory T cells in patients with systemic lupus erythema-
tosus. J Autoimmun. 2003;21:273–6.
101 Kriegel MA, Lohmann T, Gabler C, Blank N, Kalden JR, Lo-
renz HM. Defective Suppressor Function of Human CD4+
CD25+ Regulatory T Cells in Autoimmune Polyglandular
Syndrome Type II. J Exp Med. 2004;199:1285–91.
102 Balandina A, Lecart S, Dartevelle P, Saoudi A, Berrih-Aknin
S. Functional defect of regulatory CD4(+)CD25+ T cells in
the thymus of patients with autoimmune myasthenia gravis.
Blood. 2005;105:735–41.
103 Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M,
Arbery J, et al. Relation of CD4+CD25+ regulatory T-cell
suppression of allergen-driven T-cell activation to atopic sta-
tus and expression of allergic disease. Lancet. 2004;363:608–
15.
104 Karlsson MR, Rugtveit J, Brandtzaeg P. Allergen-responsive
CD4+CD25+ regulatory T cells in children who have out-
grown cow’s milk allergy. J Exp Med. 2004;199:1679–88.
105 Cavani A, Nasorri F, Ottaviani C, Sebastiani S, De Pita O,
Girolomoni G. Human CD25+ regulatory T cells maintain
immune tolerance to nickel in healthy, nonallergic indivi-
duals. J Immunol. 2003;171:5760–8.
106 Ou LS, Goleva E, Hall C, Leung DY. T regulatory cells in
atopic dermatitis and subversion of their activity by superan-
tigens. J Allergy Clin Immunol. 2004;113:756–63.
107 Mills KH. Regulatory T cells: friend or foe in immunity to
infection? Nat Rev Immunol. 2004;4:841–55.
108 Pasare C, Medzhitov R. Toll pathway-dependent blockade of
CD4+CD25+ T cell-mediated suppression by dendritic cells.
Science. 2003;299:1033–6.
109 Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon
DF. Human CD4+ CD25+ regulatory T cells control T-cell
responses to human immunodeficiency virus and cytomega-
lovirus antigens. J Virol. 2004;78:2454–9.
110 Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C, Nelson
DR. An immunomodulatory role for CD4(+)CD25(+) regu-
latory T lymphocytes in hepatitis C virus infection. Hepato-
logy. 2004;40:1062–71.
111 Kinter AL, Hennessey M, Bell A, Kern S, Lin Y, Daucher M,
et al. CD25(+)CD4(+) regulatory T cells from the peripheral
blood of asymptomatic HIV-infected individuals regulate
CD4(+) and CD8(+) HIV-specific T cell immune responses
in vitro and are associated with favorable clinical markers of
disease status. J Exp Med. 2004;200:331–43.
112 Suvas S, Kumaraguru U, Pack CD, Lee S, Rouse BT.
CD4+CD25+ T cells regulate virus-specific primary and me-
mory CD8+ T cell responses. J Exp Med. 2003;198:889–901.
113 Toka FN, Suvas S, Rouse BT. CD4+ CD25+ T cells regulate
vaccine-generated primary and memory CD8+ T-cell re-
sponses against herpes simplex virus type 1. J Virol.
2004;78:13082–9.
114 Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL.
CD4+CD25+ regulatory T cells control Leishmania major
persistence and immunity. Nature. 2002;420:502–7.
115 Belkaid Y, Rouse BT. Natural regulatory T cells in infectious
disease. Nat Immunol. 2005;6:353–60.
116 Golshayan D, Buhler L, Lechler RI, Pascual M. From cur-
rent immunosuppressive strategies to clinical tolerance of al-
lografts. Transpl Int. 2007;20:12–24.
117 Golshayan D, Jiang S, Tsang J, Garin MI, Mottet C, Lechler
RI. In vitro-expanded donor alloantigen-specific
CD4+CD25+ regulatory T cells promote experimental
transplantation tolerance. Blood. 2007;109:827–35.
118 Rieger K, Loddenkemper C, Maul J, Fietz T, Wolff D, Terpe
H, et al. Mucosal FOXP3+ regulatory T cells are numerically
deficient in acute and chronic GvHD. Blood. 2006;107:
1717–23.
119 Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah
S, et al. Reduced frequency of FOXP3+ CD4+CD25+ regula-
tory T cells in patients with chronic graft-versus-host
disease. Blood. 2005;106:2903–11.
120 Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii
H. Increased populations of regulatory T cells in peripheral
blood and tumor-infiltrating lymphocytes in patients with
gastric and esophageal cancers. Clin Cancer Res. 2003;9:
4404–8.
121 Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V,
Doherty G, et al. Prevalence of regulatory T cells is increased
in peripheral blood and tumor microenvironment of patients
with pancreas or breast adenocarcinoma. J Immunol.
2002;169:2756–61.
122 Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Du-
bertret L, et al. Foxp3 expressing CD4+CD25(high) regula-
tory T cells are overrepresented in human metastatic mela-
noma lymph nodes and inhibit the function of infiltrating T
cells. J Immunol. 2004;173:1444–53.
123 Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley
JL, et al. Cutting edge: Regulatory T cells from lung cancer
patients directly inhibit autologous T cell proliferation. J Im-
munol. 2002;168:4272–6.
124 Jiang S, Camara N, Lombardi G, Lechler RI. Induction of al-
lopeptide-specific human CD4+CD25+ regulatory T cells ex
vivo. Blood. 2003;102:2180–6.
125 Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, et al.
In vitro-expanded antigen-specific regulatory T cells sup-
press autoimmune diabetes. J Exp Med. 2004;199:1455–65.
126 Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM.
CD25+ CD4+ T cells, expanded with dendritic cells presen-
ting a single autoantigenic peptide, suppress autoimmune
diabetes. J Exp Med. 2004;199:1467–77.
127 Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selecti-
vely expands CD4+CD25+FoxP3+ regulatory T cells. Blood.
2005;105:4743–8.
634CD4+CD25+Foxp3+ regulatory T cells
625-634 Mot 11916-07.qxp  8.11.2007  9:23 Uhr  Seite 634
What Swiss Medical Weekly has to offer:
• SMW’s impact factor has been steadily 
rising. The 2005 impact factor is 1.226.
• Open access to the publication via
the Internet, therefore wide audience 
and impact
• Rapid listing in Medline
• LinkOut-button from PubMed 
with link to the full text 
website http://www.smw.ch (direct link
from each SMW record in PubMed)
• No-nonsense submission – you submit 
a single copy of your manuscript by 
e-mail attachment 
• Peer review based on a broad spectrum 
of international academic referees
• Assistance of our professional statistician
for every article with statistical analyses
• Fast peer review, by e-mail exchange with
the referees 
• Prompt decisions based on weekly confer-
ences of the Editorial Board
• Prompt notification on the status of your
manuscript by e-mail
• Professional English copy editing
• No page charges and attractive colour 
offprints at no extra cost
Editorial Board
Prof. Jean-Michel Dayer, Geneva
Prof. Peter Gehr, Berne
Prof. André P. Perruchoud, Basel
Prof. Andreas Schaffner, Zurich 
(Editor in chief)
Prof. Werner Straub, Berne
Prof. Ludwig von Segesser, Lausanne
International Advisory Committee
Prof. K. E. Juhani Airaksinen, Turku, Finland
Prof. Anthony Bayes de Luna, Barcelona, Spain
Prof. Hubert E. Blum, Freiburg, Germany
Prof. Walter E. Haefeli, Heidelberg, Germany
Prof. Nino Kuenzli, Los Angeles, USA
Prof. René Lutter, Amsterdam, 
The Netherlands
Prof. Claude Martin, Marseille, France
Prof. Josef Patsch, Innsbruck, Austria
Prof. Luigi Tavazzi, Pavia, Italy
We evaluate manuscripts of broad clinical
interest from all specialities, including experi-
mental medicine and clinical investigation.
We look forward to receiving your paper!
Guidelines for authors:
http://www.smw.ch/set_authors.html
All manuscripts should be sent in electronic form, to:
EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnsburgerstrasse 8
CH-4132 Muttenz
Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch
The many reasons why you should 
choose SMW to publish your research 
Editores Medicorum Helveticorum
S w i s s  M e d i c a l  W e e k l y
E s t a b l i s h e d  i n  1 8 7 1
F o r m e r l y :  S c h w e i ze r i s c h e  M e d i z i n i s c h e  W o c h e n s c h r i f t
O f f i c i a l  j o u r n a l  o f t h e  S w i s s  S o c i e t y  o f  I n f e c t i o u s
d i s e a s e s ,  t h e  S w i s s  S o c i e t y  o f  I n t e r n a l  M e d i c i n e
a n d  t h e  S w i s s  R e s p i r a t o r y  S o c i e t y
